Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

H. Tanaka, G. X. Yang, N. Iwakoshi, S. J. Knechtle, K. Kawata, K. Tsuneyama, Patrick S Leung, R. L. Coppel, A. A. Ansari, T. Joh, Christopher Bowlus, M. Eric Gershwin

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Summary: While there have been significant advances in our understanding of the autoimmune responses and the molecular nature of the target autoantigens in primary biliary cirrhosis (PBC), unfortunately these data have yet to be translated into new therapeutic agents. We have taken advantage of a unique murine model of autoimmune cholangitis in which mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII), under the control of the CD4 promoter, develop an intense autoimmune cholangitis associated with serological features similar to human PBC. CD40-CD40 ligand (CD40L) is a major receptor-ligand pair that provides key signals between cells of the adaptive immune system, prompting us to determine the therapeutic potential of treating autoimmune cholangitis with anti-CD40L antibody (anti-CD40L; MR-1). Four-week-old dnTGFβRII mice were injected intraperitoneally with either anti-CD40L or control immunoglobulin (Ig)G at days 0, 2, 4 and 7 and then weekly until 12 or 24 weeks of age and monitored for the progress of serological and histological features of PBC, including rigorous definition of liver cellular infiltrates and cytokine production. Administration of anti-CD40L reduced liver inflammation significantly to 12 weeks of age. In addition, anti-CD40L initially lowered the levels of anti-mitochondrial autoantibodies (AMA), but these reductions were not sustained. These data indicate that anti-CD40L delays autoimmune cholangitis, but the effect wanes over time. Further dissection of the mechanisms involved, and defining the events that lead to the reduction in therapeutic effectiveness will be critical to determining whether such efforts can be applied to PBC.

Original languageEnglish (US)
Pages (from-to)364-371
Number of pages8
JournalClinical and Experimental Immunology
Volume174
Issue number3
DOIs
StatePublished - Dec 2013

Fingerprint

CD40 Ligand
Cholangitis
Monoclonal Antibodies
Biliary Liver Cirrhosis
Growth Factor Receptors
Transforming Growth Factors
Liver
Autoantigens
Autoimmunity
Autoantibodies
Dissection
Anti-Idiotypic Antibodies
Immune System
Therapeutics
Immunoglobulin G
Cytokines
Ligands
Inflammation

Keywords

  • Anti-CD40 ligand antibody
  • Autoimmunity
  • Cholangitis
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. / Tanaka, H.; Yang, G. X.; Iwakoshi, N.; Knechtle, S. J.; Kawata, K.; Tsuneyama, K.; Leung, Patrick S; Coppel, R. L.; Ansari, A. A.; Joh, T.; Bowlus, Christopher; Gershwin, M. Eric.

In: Clinical and Experimental Immunology, Vol. 174, No. 3, 12.2013, p. 364-371.

Research output: Contribution to journalArticle

Tanaka, H, Yang, GX, Iwakoshi, N, Knechtle, SJ, Kawata, K, Tsuneyama, K, Leung, PS, Coppel, RL, Ansari, AA, Joh, T, Bowlus, C & Gershwin, ME 2013, 'Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis', Clinical and Experimental Immunology, vol. 174, no. 3, pp. 364-371. https://doi.org/10.1111/cei.12193
Tanaka, H. ; Yang, G. X. ; Iwakoshi, N. ; Knechtle, S. J. ; Kawata, K. ; Tsuneyama, K. ; Leung, Patrick S ; Coppel, R. L. ; Ansari, A. A. ; Joh, T. ; Bowlus, Christopher ; Gershwin, M. Eric. / Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. In: Clinical and Experimental Immunology. 2013 ; Vol. 174, No. 3. pp. 364-371.
@article{f6033db404cd481e80d9ae28a2445d3d,
title = "Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis",
abstract = "Summary: While there have been significant advances in our understanding of the autoimmune responses and the molecular nature of the target autoantigens in primary biliary cirrhosis (PBC), unfortunately these data have yet to be translated into new therapeutic agents. We have taken advantage of a unique murine model of autoimmune cholangitis in which mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII), under the control of the CD4 promoter, develop an intense autoimmune cholangitis associated with serological features similar to human PBC. CD40-CD40 ligand (CD40L) is a major receptor-ligand pair that provides key signals between cells of the adaptive immune system, prompting us to determine the therapeutic potential of treating autoimmune cholangitis with anti-CD40L antibody (anti-CD40L; MR-1). Four-week-old dnTGFβRII mice were injected intraperitoneally with either anti-CD40L or control immunoglobulin (Ig)G at days 0, 2, 4 and 7 and then weekly until 12 or 24 weeks of age and monitored for the progress of serological and histological features of PBC, including rigorous definition of liver cellular infiltrates and cytokine production. Administration of anti-CD40L reduced liver inflammation significantly to 12 weeks of age. In addition, anti-CD40L initially lowered the levels of anti-mitochondrial autoantibodies (AMA), but these reductions were not sustained. These data indicate that anti-CD40L delays autoimmune cholangitis, but the effect wanes over time. Further dissection of the mechanisms involved, and defining the events that lead to the reduction in therapeutic effectiveness will be critical to determining whether such efforts can be applied to PBC.",
keywords = "Anti-CD40 ligand antibody, Autoimmunity, Cholangitis, Primary biliary cirrhosis",
author = "H. Tanaka and Yang, {G. X.} and N. Iwakoshi and Knechtle, {S. J.} and K. Kawata and K. Tsuneyama and Leung, {Patrick S} and Coppel, {R. L.} and Ansari, {A. A.} and T. Joh and Christopher Bowlus and Gershwin, {M. Eric}",
year = "2013",
month = "12",
doi = "10.1111/cei.12193",
language = "English (US)",
volume = "174",
pages = "364--371",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

AU - Tanaka, H.

AU - Yang, G. X.

AU - Iwakoshi, N.

AU - Knechtle, S. J.

AU - Kawata, K.

AU - Tsuneyama, K.

AU - Leung, Patrick S

AU - Coppel, R. L.

AU - Ansari, A. A.

AU - Joh, T.

AU - Bowlus, Christopher

AU - Gershwin, M. Eric

PY - 2013/12

Y1 - 2013/12

N2 - Summary: While there have been significant advances in our understanding of the autoimmune responses and the molecular nature of the target autoantigens in primary biliary cirrhosis (PBC), unfortunately these data have yet to be translated into new therapeutic agents. We have taken advantage of a unique murine model of autoimmune cholangitis in which mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII), under the control of the CD4 promoter, develop an intense autoimmune cholangitis associated with serological features similar to human PBC. CD40-CD40 ligand (CD40L) is a major receptor-ligand pair that provides key signals between cells of the adaptive immune system, prompting us to determine the therapeutic potential of treating autoimmune cholangitis with anti-CD40L antibody (anti-CD40L; MR-1). Four-week-old dnTGFβRII mice were injected intraperitoneally with either anti-CD40L or control immunoglobulin (Ig)G at days 0, 2, 4 and 7 and then weekly until 12 or 24 weeks of age and monitored for the progress of serological and histological features of PBC, including rigorous definition of liver cellular infiltrates and cytokine production. Administration of anti-CD40L reduced liver inflammation significantly to 12 weeks of age. In addition, anti-CD40L initially lowered the levels of anti-mitochondrial autoantibodies (AMA), but these reductions were not sustained. These data indicate that anti-CD40L delays autoimmune cholangitis, but the effect wanes over time. Further dissection of the mechanisms involved, and defining the events that lead to the reduction in therapeutic effectiveness will be critical to determining whether such efforts can be applied to PBC.

AB - Summary: While there have been significant advances in our understanding of the autoimmune responses and the molecular nature of the target autoantigens in primary biliary cirrhosis (PBC), unfortunately these data have yet to be translated into new therapeutic agents. We have taken advantage of a unique murine model of autoimmune cholangitis in which mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII), under the control of the CD4 promoter, develop an intense autoimmune cholangitis associated with serological features similar to human PBC. CD40-CD40 ligand (CD40L) is a major receptor-ligand pair that provides key signals between cells of the adaptive immune system, prompting us to determine the therapeutic potential of treating autoimmune cholangitis with anti-CD40L antibody (anti-CD40L; MR-1). Four-week-old dnTGFβRII mice were injected intraperitoneally with either anti-CD40L or control immunoglobulin (Ig)G at days 0, 2, 4 and 7 and then weekly until 12 or 24 weeks of age and monitored for the progress of serological and histological features of PBC, including rigorous definition of liver cellular infiltrates and cytokine production. Administration of anti-CD40L reduced liver inflammation significantly to 12 weeks of age. In addition, anti-CD40L initially lowered the levels of anti-mitochondrial autoantibodies (AMA), but these reductions were not sustained. These data indicate that anti-CD40L delays autoimmune cholangitis, but the effect wanes over time. Further dissection of the mechanisms involved, and defining the events that lead to the reduction in therapeutic effectiveness will be critical to determining whether such efforts can be applied to PBC.

KW - Anti-CD40 ligand antibody

KW - Autoimmunity

KW - Cholangitis

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=84886312305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886312305&partnerID=8YFLogxK

U2 - 10.1111/cei.12193

DO - 10.1111/cei.12193

M3 - Article

VL - 174

SP - 364

EP - 371

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -